Kindred Healthcare Announces Proposal to Acquire Gentiva Health Services for $14.00 Per Share in Cash and Stock, Representing a 64% Premium, in $1.6 Billion Transaction

Combination Places Patient-Centered Integrated Care Front and Center, Helping to Shape the Evolution of the American Healthcare Delivery System

Gentiva Shareholders Would Benefit from Significant and Immediate Premium, Meaningful Dividend, Accelerated Growth and Enhanced Financial Strength of the Combined Company

Combination Would Create Premier Post-Acute Care Provider Serving Nearly 127,000 Patients per Day in 47 States, Employing Approximately 110,000 Individuals and Generating Pro Forma Annual Revenues of Approximately $7.2 Billion and EBITDAR of Nearly $1 Billion

Compelling Financial and Strategic Benefits; Transaction Expected to be Highly Accretive to Kindred Earnings and Cash Flows and Create Significant Value for Shareholders of Both Companies

Gentiva® Health Services Reports First Quarter 2014 Results

ATLANTA, May 7, 2014 -- Gentiva Health Services, Inc. (GTIV), one of the largest providers of home health, hospice and community care services in the United States, today reported first quarter 2014 results. 

Gentiva acquired Harden Healthcare Holdings, Inc. ("Harden") on October 18, 2013.  The Company's results for the three months ended March 31, 2014 included Harden's financial results.

First quarter 2014 financial highlights include: 

Catamaran Corporation announces strong first quarter financial results

SCHAUMBURG, Il, May 1, 2014 - Catamaran Corporation ("Catamaran" or the "Company") (NASDAQ:CTRX - News) (TSX:CCT.TO - News), a leading provider of pharmacy benefit management ("PBM") services and technology, announces its financial results for the three-month period ended March 31, 2014.

Q1 2014 Highlights

• Revenue increased 53% to $4.9 billion in Q1 2014, compared to $3.2 billion in Q1 2013
• Gross profit increased 27% to $314.7 million in Q1 2014, compared to $248.4 million in Q1 2013
• EBITDA¹ increased 19% to $170.9 million in Q1 2014, compared to $143.5 million in Q1 2013
• Net income attributable to the Company increased 23% to $63.4 million, or $0.31 per share (fully-diluted) in Q1 2014, compared to $51.4 million, or $0.25 per share (fully-diluted) in Q1 2013

Organovo Announces Pre-Release Availability of 3D Liver Contract Services

Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has initiated contracting for toxicity testing using its 3D Human Liver Tissue for selected clients prior to full release.

Organovo's Chairman and Chief Executive Officer, Keith Murphy, commented "Organovo has received interest in advance of our planned launch from top 15 pharma company customers, small to midsize pharma companies, biotechnology companies, and private venture capital backed pharmaceutical development firms.